184 related articles for article (PubMed ID: 37739951)
21. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
[TBL] [Abstract][Full Text] [Related]
22. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
23. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
[TBL] [Abstract][Full Text] [Related]
24. Remodeling of Tumor Microenvironment by Tumor-Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy.
Zhu L; Liu J; Zhou G; Liu TM; Dai Y; Nie G; Zhao Q
Small; 2021 Oct; 17(43):e2102624. PubMed ID: 34378338
[TBL] [Abstract][Full Text] [Related]
25. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
26. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL
Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579
[TBL] [Abstract][Full Text] [Related]
27. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
[TBL] [Abstract][Full Text] [Related]
28. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Xie YJ; Dougan M; Jailkhani N; Ingram J; Fang T; Kummer L; Momin N; Pishesha N; Rickelt S; Hynes RO; Ploegh H
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7624-7631. PubMed ID: 30936321
[TBL] [Abstract][Full Text] [Related]
29. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer.
Li S; Zhang M; Wang M; Wang H; Wu H; Mao L; Zhang M; Li H; Zheng J; Ma P; Wang G
Cell Death Discov; 2023 May; 9(1):147. PubMed ID: 37149721
[TBL] [Abstract][Full Text] [Related]
30. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.
Tang X; Liu F; Liu Z; Cao Y; Zhang Z; Wang Y; Huang J; Fan S; Zhao S; Chen Y; Li G; Wang S; Zheng M; Hu Y; Li H; Jiang C; Yang M; Yang H; Xu J; Guo G; Tong A; Zhou L
Clin Transl Immunology; 2020; 9(6):e1137. PubMed ID: 32547742
[TBL] [Abstract][Full Text] [Related]
31. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
[TBL] [Abstract][Full Text] [Related]
32. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
[TBL] [Abstract][Full Text] [Related]
33. Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient.
Hu G; Li G; Wen W; Ding W; Zhou Z; Zheng Y; Huang T; Ren J; Chen R; Zhu D; He R; Liang Y; Luo M
Front Oncol; 2022; 12():956593. PubMed ID: 36059640
[TBL] [Abstract][Full Text] [Related]
34. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract][Full Text] [Related]
35. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
36. The Application of Nanobody in CAR-T Therapy.
Bao C; Gao Q; Li LL; Han L; Zhang B; Ding Y; Song Z; Zhang R; Zhang J; Wu XH
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33567640
[TBL] [Abstract][Full Text] [Related]
37. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW; Pan CM; Lin YC; Chen MC; Chen Y; Jan CI; Wu CC; Lin FY; Wang ST; Lin CY; Lin PY; Huang WH; Chiang YT; Tsai WC; Chiu YH; Lin TH; Chiu SC; Cho DY
Adv Sci (Weinh); 2023 Jun; 10(17):e2206856. PubMed ID: 37078788
[TBL] [Abstract][Full Text] [Related]
38. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
39. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
40. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
